(NewsNation) — Cannabis companies have been accused of not properly warning users of health issues related to their products, a new federal class-action lawsuit states.
The complaint, filed by Weitz & Luxenberg, targets companies in 13 states and is brought by consumers who claim the products were deceptively marketed.
“These manufacturers make representations about health benefits that are unfounded while failing to warn about health risks,” said Weitz & Luxenberg’s James Bilsborrow in a news release.
Cannabis companies have been accused of not properly warning users of health issues related to their products, a new federal class-action lawsuit states.
The complaint, filed by Weitz & Luxenberg, targets companies in 13 states and is brought by consumers who claim the products were deceptively marketed.
“These manufacturers make representations about health benefits that are unfounded while failing to warn about health risks,” said Weitz & Luxenberg’s James Bilsborrow in a news release.
Lawsuit links cannabis use to mental health conditions
The lawsuit also argues that cannabis has been linked to mental health conditions, citing a 2017 report from the National Academy of Sciences.
“There is substantial evidence of a statistical association between cannabis use and the development of schizophrenia or other psychoses, with the highest risk among the most frequent users,” the complaint reads.
The plaintiffs also allege the products caused economic harm, arguing they overpaid or purchased items they might not have if they had known of the risks involved.
Cannabis hyperemesis syndrome cases on the rise for years
Health care providers across the country in March reported spikes in cases of cannabinoid (or cannabis) hyperemesis syndrome, or CHS, a painful, sometimes debilitating condition linked to chronic, long-term marijuana use.
A 2025 study found that 4.4 out of 100,000 emergency department visits were diagnosed as CHS in 2016. In 2020, the rate jumped to 33.1 per 100,000 visits before dropping in 2022 to 22.3 per 100,000.
The World Health Organization added CHS to its diagnostic manual in October 2025.
